Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 10, 2026
Immunome Inc. (IMNM)
A forensic read on Immunome Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
12.8
Distress distance
3
Forensic signals
-52.1%
ROE
-23.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Immunome Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 12.8, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+109.8%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +340% over the last 2 years to FY2025 (+109.8%/yr). The count is growing — 19.8M shares in FY2023, 87.4M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~109.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~77%.
n/m (sign flip)
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets flipped from positive to negative FY2024→FY2025 (FY2024 $+37.8M to FY2025 $-19.1M) — the standard accruals ratio divides by the average of the two, which collapses toward zero right as the sign changes, so the resulting percentage is a denominator artifact, not a real accrual measurement. Treat this as a structural balance-sheet shift to understand on its own terms rather than a clean or dirty accruals read.Accruals ratio: the year-over-year change in net operating assets, relative to their own average.NOA (net operating assets): the money tied up in running the business, operating assets minus operating liabilities.
370% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 370% of revenue in FY2025 — about $0.29 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 109.8% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$6.9M
Revenue Growth YoY-23.2%
Revenue CAGR (2yr)-29.6%
Net Margin-3060.0%
Free Cash Flow-$200.6M
Return on Equity-52.1%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Immunome Inc.'s actual 10-K/10-Q/8-K filings?